32 studies found for:    mdv3100 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: enzalutamide
2 Recruiting Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: exemestane;   Drug: Placebo (for enzalutamide)
3 Recruiting Enzalutamide in Patients With High-risk Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: enzalutamide
4 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Abiraterone;   Drug: Placebo for Enzalutamide;   Drug: Prednisone
6 Not yet recruiting LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: bicalutamide;   Procedure: orchiectomy;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Other: laboratory biomarker analysis
7 Not yet recruiting RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
Condition: Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Testosterone Enanthate;   Drug: Abiraterone acetate;   Drug: Enzalutamide
8 Recruiting Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Enzalutamide;   Drug: LHRHa
9 Recruiting Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Other: laboratory biomarker analysis
10 Recruiting Enzalutamide + External Beam Rt For Prostate
Condition: Intermediate Risk Prostate Cancer
Interventions: Drug: Enzalutamide;   Radiation: External Beam Radiation
11 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Condition: Nonmetastatic Castration-Resistant Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo
12 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
13 Recruiting Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Condition: Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: Androgen Deprivation;   Radiation: Radiation Therapy
14 Not yet recruiting A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
15 Recruiting A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Condition: Metastatic Castration- Resistant Prostate Cancer (mCRCP)
Intervention: Drug: Enzalutamide
16 Not yet recruiting Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Goserelin acetate;   Drug: Leuprolide acetate;   Radiation: Radiation therapy
17 Not yet recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
18 Recruiting Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
19 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma.
Intervention: Drug: Enzalutamide
20 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years